RGR

Business Context and Reporting Period

Company: Sturm, Ruger & Co. Inc. (RGR)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and nine months ended September 27, 2025
Business Overview: The Company designs, manufactures, and sells firearms (99% of sales) and investment castings (1% of sales) primarily to the U.S. domestic market. Operations are concentrated in the United States.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue: Net sales increased 3.7% in Q3 and 1.3% for the nine months ended September 27, 2025, driven by demand for new products (RXM pistol, Marlin lever-actions, American Centerfire Rifle Gen II), partially offset by a reduced average selling price and the discontinuation of 67,000 units of legacy models.
• Profitability Decline: Gross margin contracted significantly to 13.7% for the nine months (vs. 20.8% prior year). This was primarily due to a $17.0 million inventory rationalization write-off, increased material costs, and a product mix shift toward lower-margin items.
• Operating Expenses: General and administrative expenses rose 36.3% in Q3 and 25.4% for the nine months, attributed to leadership transition costs, organizational realignment, and professional fees related to the Anderson Manufacturing acquisition.
• Acquisition: On July 1, 2025, the Company acquired Anderson Manufacturing for $15.8 million to expand production capabilities. This included property, equipment, inventory, and intellectual property.

Outlook, Risks, and Unusual Items

• Strategic Initiatives: Management is executing an inventory rationalization and product repositioning strategy to address market conditions. These actions reduced diluted EPS by $1.46 for the nine-month period.
• Capital Allocation: The Company repurchased 730,665 shares for $26.0 million during the nine months. A dividend of $0.04 per share was declared on October 31, 2025. Approximately $14.3 million remains authorized for future stock repurchases.
• Activist Defense: On October 14, 2025, the Board adopted a limited-duration stockholder rights plan ("Poison Pill") effective until October 13, 2026, in response to Beretta Holding S.A. accumulating a significant economic interest in the Company.
• Litigation: The Company faces ongoing municipal litigation (Gary, Buffalo, Rochester) and product liability claims. A lawsuit filed by Mexico was dismissed in August 2025 following a Supreme Court decision. Management does not believe pending litigation will have a material adverse effect on financial position, though it may impact results in specific periods.
• Insurance: The Company established a wholly-owned captive insurance company for product liability claims made on or after September 1, 2024, after not renewing coverage with incumbent carriers.

Investor Verification Checklist

• Inventory Write-offs: Verify the $17.0 million inventory and asset write-off related to the revised product roadmap and its impact on future cost of goods sold.
• Product Mix: Assess the sustainability of the shift toward lower-margin products and the performance of new product introductions (RXM, Marlin, Gen II).
• Beretta Rights Plan: Monitor the status of discussions with Beretta Holding S.A. and the potential impact of the rights plan on the stock price and control dynamics.
• Litigation Exposure: Review the status of municipal lawsuits (Gary, Buffalo, Rochester) and the adequacy of the captive insurance structure for future product liability claims.
• Leadership Transition: Evaluate the long-term impact of the new CEO and organizational realignment on operating expense efficiency.